Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial.

Benzinga

New York

United States

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update - Cassava Sciences (NASDAQ:SAVA)

Ad Fontes Media

Media Bias/Fact Check

Cassava Sciences stock crashed Monday after its Alzheimer's treatment failed a key test. SAVA stock is set to open at a four-year low.

All Sides

Investor's Business Daily

Cassava Plummets 85% After Embattled Alzheimer's Drug Flops

In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer’s drug, simufilam.  Then, in September, the Securities and Exchange Commission (SEC) settled with Cassava over charges that the company had misled investors about the effectiveness of its new drug.  And today, Cassava announced that its Phase 3 trials of simuf…

Fast Company

Joe Mansueto

Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer’s disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.  The experimental treatment, simufilam, has been at the center of scrutiny after a medical professor linked to its development was charged with fraud in June.  Neuroscientist Hoau-Yan Wang allegedly submitted false data to get millions of dolla…

regionalmedianews.com

Cassava shares sink on plans to stop Alzheimer’s drug studies - Regional Media News

The biotech says it will discontinue a second trial but will still offer full analyses of the data. Article Attribution | Read More at Article Source The post Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals appeared first on RocketNews.

RocketNews

Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals

$SAVA - CASSAVA SCIENCES TOPLINE PHASE 3 DATA DID NOT MEET CO-PRIMARY ENDPOINTS CASSAVA SCIENCES INC: SIMUFILAM CONTINUED TO DEMONSTRATE AN OVERALL FAVORABLE SAFETY PROFILE CASSAVA SCIENCES INC: SIMUFILAM DID NOT SHOW A SIGNIFICANT REDUCTION IN COGNITIVE OR FUNCTIONAL DECLINE VERSUS PLACEBO

franktrades.com

📰 $SAVA – CASSAVA SCIENCES TOPLINE PHASE 3 DATA DID NOT MEET CO-PRIMARY ENDPOINTS CASSAVA SCIENCES INC: SIMUFILAM CONTINUED TO DEMONSTRATE AN OVERALL FAVORABLE SAFETY PROFILE CASSAVA SCIENCES INC: SIMUFILAM DID NOT SHOW A SIGNIFICANT REDUCTION IN COGNITIV

On November 25th, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase 3 trial.... The post Cassava Drug Simufilam Fails First Phase 3 Trial, Halts Second Phase 3 Trial appeared first on Being Patient.

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update - Cassava Sciences (NASDAQ:SAVA)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics